Cite
HARVARD Citation
Mesegué, M. et al. (2021). Lower incidence of clinical allergy with PEG‐asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG‐ASP in pediatric patients with acute lymphoblastic leukemia. Hematological oncology. 39 (5), pp. 687-696. [Online].